Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria

Gut

Volumn 38, Issue 3, 1996, Pages 365-375

  Macpherson, A ^a   Khoo, U Y ^a   Forgacs, I ^a   Philpott Howard, J ^a   Bjarnason, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammatory bowel disease; Intestinal bacteria; Mucosal antibodies

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; LYMPHOCYTE; MALE; PRIORITY JOURNAL;

EID: 0029866466     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.3.365     Document Type: Article

References (48)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991; 325: 928-37, 1008-16.
2. Macdermott RP, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 1988; 42: 285-328.
3. Teahon K, Smethurst P, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991; 101: 84-9.
4. Teahon K, Smethurst P, Macpherson AJ, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol and Hepatol 1993; 5: 79-84.
5. Bjarnason I, Macpherson A, Menzies IS. Intestinal permeability: the basics. In: Sutherland LR, Collins SM, Martin F, McLeod RS, Targan SR, Wallace JL, Williams CN, eds. Inflammatory bowel disease. Basic research, clinical implications and trends in therapy. Dordrecht: Kluwer Academic, 1994: 53-70.
6. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastronterology 1995; 108: 1566-81.
7. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the predictor of relapse in Crohn's disease. Lancet 1993; 341: 1437-9.
8. Lee E. Split ileostomy in the treatment of Crohn's disease of the colon. Ann R Coll Surg Eng 1975; 56: 94-102.
9. Rutgeerts P, Goboes K, Peeters M, Hiele M, Pennickx F, Aerts R, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-4.
10. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993; 75: 275-82.
11. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
12. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin- 10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
13. Sartor RB. Role of the intestinal microflora in pathogenesis and complications. In: Scholmeric J, Kruis W, Goebbell H, Hohenberger W, Gross V, eds. Inflammatory bowel diseases: pathophysiology as basis of treatment. Falk Symposium No 67. Lancaster: Kluwer Academic 1993: 175-87.
14. Thayer H, Brown M, Sangree MH, Katz J, Hersh T. Escherichia coli 0:14 and colon haemaglutinating antibodies in inflammatory bowel disease. Gastroenterology 1969; 57: 311-8.
15. Heddle RJ, Shearman DJC. Serum antibodies to Escherichia coli in subjects with ulcerative colitis. Clin Exp Immunol 1979; 38: 22-30.
16. Langercrantz R, Hammerström S, Perlmann P, Gustafsson BE. Clin Exp Immunol 1966; 1: 263-76.
17. Carlsson HK, Langercrantz R, Perlmann P. Immunological studies in inflammatory bowel disease VIII. Stand J Gastroenterol 1977; 12: 707-14.
18. Bull DM, Ignaczak TF. Enterobacterial common antigen-induced lymphocyte reactivity in inflammatory bowel disease. Gastroenterology 1973; 64: 43-9.
19. Bartnik W, Swarbrick ET, Williams C. A study of peripheral leucocyte migration in agarose medium in inflammatory bowel disease. Gut 1974; 15: 294-300.
20. Brandtzaeg P, Baklien K, Fausa O, Hoel PS. Immunohistochemical characterisation of local immunoglobulin formation in ulcerative colitis. Gastroenterology 1974; 66: 1123-36.
21. Baklien K, Brandtzaeg P. Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin Exp Immunol 1975; 22: 197-209.
22. Rosekrans PCM, Meijer CJLM, Van der Wal AM, Cornelisse CJ, Lindeman J. Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut 1980; 21: 941-7.
23. Scott BB, Goodall A, Stephenson P, Jenkins D. Rectal mucosal plasma cells in inflammatory bowel disease. Gut 1983; 24: 519-24.
24. Keren DF, Kern SE, Bauer DH. Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol 1982; 128: 475-9.
25. Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP. Spontaneous secretion of IgG sub-classes by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol 1986; 66: 209-15.
26. Rüthlein J, Ibe M, Burghardt W, Mössner J, Auer IO. Immunoglobulin G (IgG), IgG1, and IgG2 determinations from endoscopie biopsy specimens in control, Crohn's disease and ulcerative colitis subjects. Gut 1992; 33: 507-12.
27. Chao LP, Steele J, Rodrigues C, Lennard-Jones J, Stanford JL, Spiliadis C, et al. Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel disease. Gut 1988; 29: 35-40.
28. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-2.
29. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
30. Morson BC, Dawson IMP, Day DW, Jass JR, Price AB, Williams GT. Gastrointestinal pathology. Oxford: Blackwell Scientific, 1990.
31. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
32. Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571-4.
33. Macpherson AJS, Jones-Mortimer MC, Henderson PJF. Identification of the AraE protein of Escherichia coli. Biochem J 1981; 196: 269-93.
34. Kaback HR. Transport across isolated bacterial cytoplasmic membranes. Biochem Biophys Acta 1972; 265: 367-416.
35. Harlow E, Lane D. Antibodies - laboratory manual. New York: Cold Spring Harbor Laboratory, 1988.
36. Reinhold R, Fine J, A technique for quantitative measurement of endotoxin in human plasma. Proc Soc Exp Biol Med 1971; 137: 334-47.
37. Choudari CP, O'Mahony S, Brydon G, Mwantembe O, Ferguson A. Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1064-71.
38. Breese E, Bragger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2 and interferon-gamma secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127-131.
39. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992; 102: 1620-7.
40. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-8.
41. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994; 264: 1587-9.
42. Bachmann MF, Hoffmann Rohrer U, Kündig TM, Bürki K, Hengarter H, Zinkernagel H. The influence of antigen organisation on B cell responsiveness. Science 1993; 262: 1448-51.
43. Das KM, Erber WF, Rubinstein A. Immunohistochemical changes in morphologically involved and uninvolved colonic mucosa of patients with idiopathic proctitis. J Clin Invest 1977; 59: 379-85.
44. Engstrom JF, Arvantis C, Sagawa A, Abdou NI. Secretory immunoglobulin deficiency in a family with inflammatory bowel disease. Gastroenterology 1978; 74: 747-51.
45. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the Mr 40kd putative autoantigen in ulcerative colitis. Gut 1993; 34: 650-7.
46. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. The effects of NSAID and prostaglandins on the permeability of the human small bowel. Gut 1986; 27: 1292-7.
47. Noone C, Menzies IS, Banatvala JE, Scopes JW. Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simulateously by non-invasive differential sugar permeation. Eur J Clin Invest 1986; 6: 217-25.
48. MacQueen G, Marshall J, Perdue M, Siegel S, Bienenstock J. Pavlovian conditioning of rat mast cells to secrete rat mast cell protease II. Science 1989; 273: 83-5.